“Impact of thyroid immune-related adverse events on clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitor therapy: A single center study” (2025) Biomolecules and Biomedicine, 26(1), pp. 144–149. doi:10.17305/bb.2025.12321.